Literature DB >> 9430472

D-lysine reduction of indium-111 octreotide and yttrium-90 octreotide renal uptake.

B F Bernard1, E P Krenning, W A Breeman, E J Rolleman, W H Bakker, T J Visser, H Mäcke, M de Jong.   

Abstract

UNLABELLED: Indium-111-DTPA-octreotide (111In-DTPAOC) is used successfully for imaging somatostatin receptor-positive lesions. A new and promising application is its use in peptide-receptor radionuclide therapy (PRRT). For the latter purpose, [DOTA0,D-Phe1,Tyr3]octreotide (DOTATOC), which is suitable for stable radiolabeling with 90Y, is probably even more promising. Significant renal uptake of these octreotide analogs exists, however, reducing the scintigraphic sensitivity for detection of small tumors in the perirenal region and limiting the possibilities for PRRT. We showed that the renal uptake of 111In-DTPAOC could be reduced to about 50% of control by L-lysine administration in vivo in rats. This study compares the effects of several doses and different methods of administration of D- and L-lysine, in addition to time-related effects of D-lysine, on kidney uptake of 111In-DTPAOC and 90Y-DOTATOC.
METHODS: Male Wistar rats (200-250 g) were given 111In-DTPAOC (0.2 MBq, 0.5 microg-0.5 mg intravenously, intraperitoneally or orally) in the presence or absence of D- or L-lysine. At 1, 4 or 24 hr, the rats were killed, and the organs were isolated and counted for radioactivity. In different experiments, male Wistar rats (200-250 g) were given 90Y-DOTATOC (1 MBq, 0.5 microg intravenously) in the presence or absence of D-lysine. At 24 hr, the rats were killed, and the organs were isolated and counted for radioactivity.
RESULTS: Administration of D- or L-lysine in a single intravenous dose of 400 mg/kg, resulted in more than 50% inhibition of kidney uptake of 111In-DTPAOC at all time points tested, independently of the mass of 111In-DTPAOC used. Higher or repeated doses of lysine did not give a significantly higher percentage inhibition. D-lysine, given orally in a dose of 400 mg/kg at 30 or 15 min before 111In-DTPAOC injection, resulted in 30% and 20% inhibition of kidney uptake, respectively. L-lysine, given orally 30 min before 111In-DTPAOC administration, resulted in 30% inhibition as well. Inhibition of kidney uptake of 111In-DTPAOC by L-lysine after intraperitoneal administration was 40%. After L-lysine administration, 111In-DTPAOC was decreased in the kidneys and in somatostatin receptor-positive organs such as the pancreas and adrenal glands. In contrast, D-lysine did not have a significant effect on uptake in octreotide receptor-positive organs. Renal uptake of 90Y-DOTATOC was reduced by 65% by intravenous D-lysine, whereas radioactivity in blood, pancreas and adrenal glands was not affected.
CONCLUSION: D-lysine may be preferred to L-lysine for reduction of renal uptake of radioactivity during scintigraphy and PRRT because of its lower toxicity and because it should not interfere with the natural amino acid metabolic balance.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9430472

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  33 in total

1.  Kidney failure after treatment with 90Y-DOTATOC.

Authors:  Tilmann Schumacher; Christian Waldherr; Jan Mueller-Brand; Helmut Maecke
Journal:  Eur J Nucl Med Mol Imaging       Date:  2002-03       Impact factor: 9.236

2.  Melanoma imaging using (111)In-, (86)Y- and (68)Ga-labeled CHX-A''-Re(Arg11)CCMSH.

Authors:  Lihui Wei; Xiuli Zhang; Fabio Gallazzi; Yubin Miao; Xiaofang Jin; Martin W Brechbiel; Heng Xu; Thomas Clifford; Michael J Welch; Jason S Lewis; Thomas P Quinn
Journal:  Nucl Med Biol       Date:  2009-03-26       Impact factor: 2.408

3.  Influence of the amount of co-infused amino acids on post-therapeutic potassium levels in peptide receptor radionuclide therapy.

Authors:  Constantin Lapa; Rudolf A Werner; Christina Bluemel; Katharina Lückerath; Andreas Schirbel; Alexander Strate; Andreas K Buck; Ken Herrmann
Journal:  EJNMMI Res       Date:  2014-08-23       Impact factor: 3.138

Review 4.  Yttrium-labelled peptides for therapy of NET.

Authors:  Lisa Bodei; Marta Cremonesi; Chiara M Grana; Marco Chinol; Silvia M Baio; Stefano Severi; Giovanni Paganelli
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-02       Impact factor: 9.236

Review 5.  The role of peptide receptor radionuclide therapy in advanced/metastatic thoracic neuroendocrine tumors.

Authors:  Lisa Bodei; Jarosław B Ćwikla; Mark Kidd; Irvin M Modlin
Journal:  J Thorac Dis       Date:  2017-11       Impact factor: 2.895

6.  Gallium-68-labeled DOTA-rhenium-cyclized alpha-melanocyte-stimulating hormone analog for imaging of malignant melanoma.

Authors:  Lihui Wei; Yubin Miao; Fabio Gallazzi; Thomas P Quinn; Michael J Welch; Amy L Vāvere; Jason S Lewis
Journal:  Nucl Med Biol       Date:  2007-09-04       Impact factor: 2.408

Review 7.  Peptide receptor radionuclide therapy: focus on bronchial neuroendocrine tumors.

Authors:  Giuseppe Lo Russo; Sara Pusceddu; Natalie Prinzi; Martina Imbimbo; Claudia Proto; Diego Signorelli; Milena Vitali; Monica Ganzinelli; Marco Maccauro; Roberto Buzzoni; Ettore Seregni; Filippo de Braud; Marina Chiara Garassino
Journal:  Tumour Biol       Date:  2016-07-27

8.  A comparison of (111)In-DOTATOC and (111)In-DOTATATE: biodistribution and dosimetry in the same patients with metastatic neuroendocrine tumours.

Authors:  F Forrer; H Uusijärvi; C Waldherr; M Cremonesi; P Bernhardt; J Mueller-Brand; H R Maecke
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-06-10       Impact factor: 9.236

9.  Accurate assessment of long-term nephrotoxicity after peptide receptor radionuclide therapy with (177)Lu-octreotate.

Authors:  Amir Sabet; Khaled Ezziddin; Ulrich-Frank Pape; Karl Reichman; Torjan Haslerud; Hojjat Ahmadzadehfar; Hans-Jürgen Biersack; James Nagarajah; Samer Ezziddin
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-11-06       Impact factor: 9.236

10.  Albumin-derived peptides efficiently reduce renal uptake of radiolabelled peptides.

Authors:  Erik Vegt; Annemarie Eek; Wim J G Oyen; Marion de Jong; Martin Gotthardt; Otto C Boerman
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-09-01       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.